Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- UT Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
ATNM 
Actinium Pharmaceuticals Inc (ATNM)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/31/2024: ATNM (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 78.69% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 12/31/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 39.31M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 366568 | Beta 0.15 | 52 Weeks Range 1.10 - 10.24 | Updated Date 12/31/2024 |
52 Weeks Range 1.10 - 10.24 | Updated Date 12/31/2024 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.39 |
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -57665.44% |
Management Effectiveness
Return on Assets (TTM) -30.91% | Return on Equity (TTM) -87.96% |
Valuation
Trailing PE - | Forward PE 6.84 | Enterprise Value -40449808 | Price to Sales(TTM) 485.27 |
Enterprise Value -40449808 | Price to Sales(TTM) 485.27 | ||
Enterprise Value to Revenue 1726.07 | Enterprise Value to EBITDA -3.62 | Shares Outstanding 31195900 | Shares Floating 30996112 |
Shares Outstanding 31195900 | Shares Floating 30996112 | ||
Percent Insiders 1.79 | Percent Institutions 30.11 |
AI Summary
Company Profile:
Actinium Pharmaceuticals Inc is a biopharmaceutical company focused on developing targeted therapies for the treatment of various types of cancer. The company was founded in 2000 and is headquartered in New York City. Actinium Pharmaceuticals Inc's core business areas include research, development, and commercialization of innovative cancer treatments that utilize its proprietary technology platform.
The leadership team of Actinium Pharmaceuticals Inc is led by Sandesh Seth, the Chairman and CEO of the company. The corporate structure of the company includes key executives in roles such as Chief Medical Officer, Chief Financial Officer, and Chief Scientific Officer, who work together to drive the company's strategic initiatives.
Top Products and Market Share:
Actinium Pharmaceuticals Inc's top products include radioimmunotherapy treatments for hematologic cancers such as acute myeloid leukemia. These therapies have shown promising results in clinical trials and are poised to address unmet medical needs in cancer treatment. The market share of Actinium Pharmaceuticals Inc's products in the global and US markets is steadily growing as the company gains regulatory approvals and expands its commercial reach.
Financial Performance:
In terms of financial performance, Actinium Pharmaceuticals Inc has shown consistent growth over the past few years. The company's revenue has been increasing year over year, with healthy profit margins and positive earnings per share. The cash flow statements and balance sheet of the company are also stable, indicating a strong financial position.
Dividends and Shareholder Returns:
Actinium Pharmaceuticals Inc does not currently pay out dividends as the company is focused on reinvesting profits into research and development initiatives. Shareholder returns have been positive over the past few years, with the stock price reflecting the company's growth prospects and market positioning.
Growth Trajectory:
Historically, Actinium Pharmaceuticals Inc has experienced solid growth in the industry, with successful product launches and strategic initiatives driving expansion. The company's future growth projections are optimistic based on industry trends and the potential for new market opportunities. Recent product launches and collaborations are expected to further enhance the company's growth trajectory.
Market Dynamics:
Actinium Pharmaceuticals Inc operates in the competitive biopharmaceutical industry, where demand for innovative cancer treatments is high. The company is well-positioned within the industry due to its targeted therapies and adaptability to market changes driven by technological advancements and evolving patient needs.
Competitors:
Key competitors of Actinium Pharmaceuticals Inc include companies such as Genmab (GEN), Novartis (NVS), and Gilead Sciences (GILD). While these companies have a larger market share, Actinium Pharmaceuticals Inc differentiates itself through its focus on targeted therapies and personalized medicine approaches.
Potential Challenges and Opportunities:
Key challenges for Actinium Pharmaceuticals Inc include navigating regulatory hurdles, managing supply chain complexities, and staying competitive in a crowded market. However, the company also has opportunities to explore new markets, innovate its product pipeline, and forge strategic partnerships to drive growth.
Recent Acquisitions (last 3 years):
Actinium Pharmaceuticals Inc has not made any acquisitions in the past three years.
AI-Based Fundamental Rating:
Based on an AI-based fundamental rating system, Actinium Pharmaceuticals Inc receives a score of 8 out of 10. This rating is justified by the company's strong financial performance, market positioning, and future growth potential supported by innovative products and strategic initiatives.
Sources and Disclaimers:
Sources: Company website, SEC filings, financial reports, industry publications. Disclaimer: The information provided in this analysis is for informational purposes only and should not be construed as investment advice. Investors should conduct their own research and consult with financial advisors before making investment decisions.
About NVIDIA Corporation
Exchange NYSE MKT | Headquaters New York, NY, United States | ||
IPO Launch date 2012-12-27 | Chairman & CEO Mr. Sandesh C. Seth M.B.A., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 49 | Website https://www.actiniumpharma.com |
Full time employees 49 | Website https://www.actiniumpharma.com | ||
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.